Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression
Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men. Thus, there is a great need for new treatments to improve outcomes. One such strategy is to eliminate cancer through the expression of cytotoxic genes speci...
Saved in:
Published in | BMC biotechnology Vol. 7; no. 1; p. 9 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
12.02.2007
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men. Thus, there is a great need for new treatments to improve outcomes. One such strategy is to eliminate cancer through the expression of cytotoxic genes specifically in prostate cells by gene therapy vectored delivery. To prevent systemic toxicity, tissue- and/or cancer-specific gene expression is required. However, the use of tissue- or cancer-specific promoters to target transgene expression has been hampered by their weak activity.
To address this issue, we have developed a regulation strategy that includes feedback amplification of gene expression along with a differentially suppressible tetracycline regulated expression system (DiSTRES). By differentially suppressing expression of the tetracycline-regulated transcriptional activator (tTA) and silencer (tTS) genes based on the cell origin, this leads to the activation and silencing of the TRE promoter, respectively. In vitro transduction of LNCaP cells with Ad/GFPDiSTRES lead to GFP expression levels that were over 30-fold higher than Ad/CMV-GFP. Furthermore, Ad/FasL-GFPDiSTRES demonstrated cytotoxic effects in prostate cancer cells known to be resistant to Fas-mediated apoptosis.
Prostate-specific regulation from the DiSTRES system, therefore, serves as a promising new regulation strategy for future applications in the field of cancer gene therapy and gene therapy as a whole. |
---|---|
AbstractList | Abstract
Background
Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men. Thus, there is a great need for new treatments to improve outcomes. One such strategy is to eliminate cancer through the expression of cytotoxic genes specifically in prostate cells by gene therapy vectored delivery. To prevent systemic toxicity, tissue- and/or cancer-specific gene expression is required. However, the use of tissue- or cancer-specific promoters to target transgene expression has been hampered by their weak activity.
Results
To address this issue, we have developed a regulation strategy that includes feedback amplification of gene expression along with a differentially suppressible tetracycline regulated expression system (DiSTRES). By differentially suppressing expression of the tetracycline-regulated transcriptional activator (tTA) and silencer (tTS) genes based on the cell origin, this leads to the activation and silencing of the TRE promoter, respectively.
In vitro
transduction of LNCaP cells with Ad/
GFP
DiSTRES
lead to GFP expression levels that were over 30-fold higher than Ad/CMV-
GFP
. Furthermore, Ad/FasL-GFP
DiSTRES
demonstrated cytotoxic effects in prostate cancer cells known to be resistant to Fas-mediated apoptosis.
Conclusion
Prostate-specific regulation from the DiSTRES system, therefore, serves as a promising new regulation strategy for future applications in the field of cancer gene therapy and gene therapy as a whole. Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men. Thus, there is a great need for new treatments to improve outcomes. One such strategy is to eliminate cancer through the expression of cytotoxic genes specifically in prostate cells by gene therapy vectored delivery. To prevent systemic toxicity, tissue- and/or cancer-specific gene expression is required. However, the use of tissue- or cancer-specific promoters to target transgene expression has been hampered by their weak activity. Results To address this issue, we have developed a regulation strategy that includes feedback amplification of gene expression along with a differentially suppressible tetracycline regulated expression system (DiSTRES). By differentially suppressing expression of the tetracycline-regulated transcriptional activator (tTA) and silencer (tTS) genes based on the cell origin, this leads to the activation and silencing of the TRE promoter, respectively. In vitro transduction of LNCaP cells with Ad/GFP sub(DiSTRES )lead to GFP expression levels that were over 30-fold higher than Ad/CMV-GFP. Furthermore, Ad/FasL-GFP sub(DiSTRES )demonstrated cytotoxic effects in prostate cancer cells known to be resistant to Fas-mediated apoptosis. Conclusion Prostate-specific regulation from the DiSTRES system, therefore, serves as a promising new regulation strategy for future applications in the field of cancer gene therapy and gene therapy as a whole. Abstract Background Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men. Thus, there is a great need for new treatments to improve outcomes. One such strategy is to eliminate cancer through the expression of cytotoxic genes specifically in prostate cells by gene therapy vectored delivery. To prevent systemic toxicity, tissue- and/or cancer-specific gene expression is required. However, the use of tissue- or cancer-specific promoters to target transgene expression has been hampered by their weak activity. Results To address this issue, we have developed a regulation strategy that includes feedback amplification of gene expression along with a differentially suppressible tetracycline regulated expression system (DiSTRES). By differentially suppressing expression of the tetracycline-regulated transcriptional activator (tTA) and silencer (tTS) genes based on the cell origin, this leads to the activation and silencing of the TRE promoter, respectively. In vitro transduction of LNCaP cells with Ad/GFPDiSTRES lead to GFP expression levels that were over 30-fold higher than Ad/CMV-GFP. Furthermore, Ad/FasL-GFPDiSTRES demonstrated cytotoxic effects in prostate cancer cells known to be resistant to Fas-mediated apoptosis. Conclusion Prostate-specific regulation from the DiSTRES system, therefore, serves as a promising new regulation strategy for future applications in the field of cancer gene therapy and gene therapy as a whole. BACKGROUND: Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men. Thus, there is a great need for new treatments to improve outcomes. One such strategy is to eliminate cancer through the expression of cytotoxic genes specifically in prostate cells by gene therapy vectored delivery. To prevent systemic toxicity, tissue- and/or cancer-specific gene expression is required. However, the use of tissue- or cancer-specific promoters to target transgene expression has been hampered by their weak activity. RESULTS: To address this issue, we have developed a regulation strategy that includes feedback amplification of gene expression along with a differentially suppressible tetracycline regulated expression system (DiSTRES). By differentially suppressing expression of the tetracycline-regulated transcriptional activator (tTA) and silencer (tTS) genes based on the cell origin, this leads to the activation and silencing of the TRE promoter, respectively. In vitro transduction of LNCaP cells with Ad/GFPDiSTRES lead to GFP expression levels that were over 30-fold higher than Ad/CMV-GFP. Furthermore, Ad/FasL-GFPDiSTRES demonstrated cytotoxic effects in prostate cancer cells known to be resistant to Fas-mediated apoptosis. CONCLUSION: Prostate-specific regulation from the DiSTRES system, therefore, serves as a promising new regulation strategy for future applications in the field of cancer gene therapy and gene therapy as a whole. Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men. Thus, there is a great need for new treatments to improve outcomes. One such strategy is to eliminate cancer through the expression of cytotoxic genes specifically in prostate cells by gene therapy vectored delivery. To prevent systemic toxicity, tissue- and/or cancer-specific gene expression is required. However, the use of tissue- or cancer-specific promoters to target transgene expression has been hampered by their weak activity. To address this issue, we have developed a regulation strategy that includes feedback amplification of gene expression along with a differentially suppressible tetracycline regulated expression system (DiSTRES). By differentially suppressing expression of the tetracycline-regulated transcriptional activator (tTA) and silencer (tTS) genes based on the cell origin, this leads to the activation and silencing of the TRE promoter, respectively. In vitro transduction of LNCaP cells with Ad/GFPDiSTRES lead to GFP expression levels that were over 30-fold higher than Ad/CMV-GFP. Furthermore, Ad/FasL-GFPDiSTRES demonstrated cytotoxic effects in prostate cancer cells known to be resistant to Fas-mediated apoptosis. Prostate-specific regulation from the DiSTRES system, therefore, serves as a promising new regulation strategy for future applications in the field of cancer gene therapy and gene therapy as a whole. |
ArticleNumber | 9 |
Author | Rubinchik, Semyon Dong, John Y Yu, Hong Woraratanadharm, Jan |
AuthorAffiliation | 1 Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA 2 Division of Cancer Therapeutics, GenPhar Inc., Mount Pleasant, South Carolina, USA |
AuthorAffiliation_xml | – name: 2 Division of Cancer Therapeutics, GenPhar Inc., Mount Pleasant, South Carolina, USA – name: 1 Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA |
Author_xml | – sequence: 1 givenname: Jan surname: Woraratanadharm fullname: Woraratanadharm, Jan email: jworara@genphar.com, jworara@genphar.com organization: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA. jworara@genphar.com <jworara@genphar.com> – sequence: 2 givenname: Semyon surname: Rubinchik fullname: Rubinchik, Semyon – sequence: 3 givenname: Hong surname: Yu fullname: Yu, Hong – sequence: 4 givenname: John Y surname: Dong fullname: Dong, John Y |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17295927$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ksuP1SAUhxszxnno0q1h5coqcEspG6OZ-JhkohtdkwM9vZdJCxXoxNn7h0u9N-PcGDfA4fz4zovz6sQHj1X1nNHXjHXtG9ZIXrdS0FrW6lF1dm-fPDifVucp3VDKZEfbJ9Upk1wJxeVZ9etLuMWRpLuUcSJLwkTmGAwk5-uyYr-aU8gYX5EcwScb3Zxd8FAeuRG9xZgI-J7ANI9ucBZWLxlDmEkOxPl-sUh2brurR1xDFV7KkJHgzzliSkX9tHo8wJjw2WG_qL5__PDt8nN9_fXT1eX769qIjcq1tLyUYPhgWhAtNsClFSCQ981QqrEtbY0ApVTHBWC3sV2PhjHVDygUmGZzUV3tuX2AGz1HN0G80wGc_nMR4lZDzM6OqCmz0gDDDhvVNB1TA0gueg4AgkqhCuvtnjUvZsLeoi_tGY-gxx7vdnobbjXrGBVcFsC7PcC48B_AsceGSa8T1etEtdRrDi8POcTwY8GU9eSSxXEEj2FJmlPeSNZ0RVjvhbY0P0Uc7sMwqtdv9A_4xcPi_qoP_2bzG980yis |
CitedBy_id | crossref_primary_10_1038_cgt_2010_41 crossref_primary_10_1038_gt_2008_19 crossref_primary_10_1007_s00580_011_1355_8 |
Cites_doi | 10.1210/en.141.12.4698 10.1128/JVI.77.4.2512-2521.2003 10.1038/sj.gt.3301048 10.1038/sj.cgt.7700313 10.1006/mthe.2002.0551 10.4161/cbt.2.5.440 10.1038/sj.gt.3301845 10.1002/ijc.11563 10.1128/JVI.76.17.8621-8631.2002 10.1073/pnas.89.12.5547 10.1038/sj.gt.3302307 10.1016/S0039-128X(96)00086-4 10.1038/sj.gt.3302103 10.1006/mthe.2001.0478 10.1038/sj.gt.3301172 10.1097/01.sla.0000098622.47909.c0 10.1093/jnci/djj111 10.1038/sj.gt.3301473 10.1074/jbc.273.9.4972 10.1016/S0090-4295(03)00378-9 10.1016/S0076-6879(02)46075-2 10.1126/science.314.5803.1232 10.1038/sj.gt.3301364 10.1089/10430340260185067 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y 10.1111/j.1349-7006.2006.00243.x |
ContentType | Journal Article |
Copyright | Copyright © 2007 Woraratanadharm et al; licensee BioMed Central Ltd. 2007 Woraratanadharm et al; licensee BioMed Central Ltd. |
Copyright_xml | – notice: Copyright © 2007 Woraratanadharm et al; licensee BioMed Central Ltd. 2007 Woraratanadharm et al; licensee BioMed Central Ltd. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 5PM DOA |
DOI | 10.1186/1472-6750-7-9 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | CrossRef Engineering Research Database MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 1472-6750 |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_01c7ba1e8e4944819fa725d2aaa50759 oai_biomedcentral_com_1472_6750_7_9 10_1186_1472_6750_7_9 17295927 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: R01 DK057997 – fundername: NIDDK NIH HHS grantid: R01 DK057997-03 – fundername: NIDDK NIH HHS grantid: R01 DK57997 |
GroupedDBID | --- -A0 0R~ 23N 2VQ 2WC 4.4 53G 5GY 5VS 6J9 A8Z AAFWJ AAHBH AAJSJ ABDBF ACGFO ACGFS ACIHN ACIWK ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BFQNJ BMC C1A C24 C6C CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EJD EMB EMK EMOBN ESTFP ESX F5P GROUPED_DOAJ GX1 H13 HH5 HYE I-F IAG IAO IHR INH INR IOV IPNFZ ISR ITC ITG ITH KPI KQ8 M48 ML0 M~E NPM O5R O5S OK1 P2P PGMZT RBZ RIG RNS ROL RPM RSV RVI SCM SOJ SV3 TR2 TUS W2D WOQ WOW XSB AAYXX CITATION 7QO 8FD AFGXO FR3 P64 ABVAZ AFNRJ 5PM |
ID | FETCH-LOGICAL-b539t-7c2001b2fb6a56e4a27c5a5e2d4f592c606b5a999825ae83c8deb119dfe59ab43 |
IEDL.DBID | RPM |
ISSN | 1472-6750 |
IngestDate | Fri Oct 04 13:15:07 EDT 2024 Tue Sep 17 21:23:13 EDT 2024 Wed May 22 07:11:41 EDT 2024 Fri Aug 16 23:26:25 EDT 2024 Thu Sep 12 16:53:06 EDT 2024 Sat Sep 28 07:55:55 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b539t-7c2001b2fb6a56e4a27c5a5e2d4f592c606b5a999825ae83c8deb119dfe59ab43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1810527/ |
PMID | 17295927 |
PQID | 20247148 |
PQPubID | 23462 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_01c7ba1e8e4944819fa725d2aaa50759 pubmedcentral_primary_oai_pubmedcentral_nih_gov_1810527 biomedcentral_primary_oai_biomedcentral_com_1472_6750_7_9 proquest_miscellaneous_20247148 crossref_primary_10_1186_1472_6750_7_9 pubmed_primary_17295927 |
PublicationCentury | 2000 |
PublicationDate | 2007-02-12 |
PublicationDateYYYYMMDD | 2007-02-12 |
PublicationDate_xml | – month: 02 year: 2007 text: 2007-02-12 day: 12 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC biotechnology |
PublicationTitleAlternate | BMC Biotechnol |
PublicationYear | 2007 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 1319065 - Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 16507823 - J Natl Cancer Inst. 2006 Mar 1;98(5):298-300 17124300 - Science. 2006 Nov 24;314(5803):1232-5 9478943 - J Biol Chem. 1998 Feb 27;273(9):4972-5 14528322 - Gene Ther. 2003 Nov;10(23):1982-91 11108285 - Endocrinology. 2000 Dec;141(12):4698-710 10680019 - Gene Ther. 2000 Jan;7(1):75-9 16800821 - Cancer Sci. 2006 Aug;97(8):787-98 11863411 - Mol Ther. 2002 Mar;5(3):223-32 11708878 - Mol Ther. 2001 Nov;4(5):416-26 11809717 - Cancer Res. 2002 Jan 15;62(2):609-16 12163581 - J Virol. 2002 Sep;76(17):8621-31 8883219 - Steroids. 1996 Sep;61(9):531-9 10845726 - Gene Ther. 2000 May;7(10):875-85 14614316 - Cancer Biol Ther. 2003 Sep-Oct;2(5):511-5 12946777 - Urology. 2003 Sep;62(3):559-65 15229631 - Gene Ther. 2004 Sep;11(18):1399-407 12215264 - Hum Gene Ther. 2002 Aug 10;13(12):1427-39 12551989 - J Virol. 2003 Feb;77(4):2512-21 12530077 - Anticancer Res. 2002 Nov-Dec;22(6A):3285-92 14618628 - Int J Cancer. 2004 Jan 1;108(1):136-45 11313797 - Gene Ther. 2001 Feb;8(3):247-53 11477454 - Cancer Gene Ther. 2001 May;8(5):342-51 11438831 - Gene Ther. 2001 Jul;8(13):969-76 10738580 - J Gene Med. 1999 Jan-Feb;1(1):4-12 12526164 - Methods Mol Med. 2003;76:167-99 12571644 - Gene Ther. 2003 Jan;10(2):153-62 11883089 - Methods Enzymol. 2002;346:529-47 14631218 - Ann Surg. 2003 Dec;238(6):815-24; discussion 825-6 W Jongmans (184_CR25) 2003; 62 S Rubinchik (184_CR9) 2001; 4 S Kagawa (184_CR16) 2000; 7 S Rubinchik (184_CR12) 2000; 7 J Zhang (184_CR7) 2000; 141 DA Heideman (184_CR22) 2001; 8 JG Wesseling (184_CR21) 2001; 8 K Garber (184_CR3) 2006; 98 L Zhang (184_CR17) 2002; 5 S Rubinchik (184_CR30) 2002; 346 DM Nettelbeck (184_CR26) 2004; 108 AL Volk (184_CR18) 2003; 2 J Woraratanadharm (184_CR5) 2004; 11 S Freundlieb (184_CR8) 1999; 1 M Gossen (184_CR6) 1992; 89 A Block (184_CR13) 2002; 22 CJ Buskens (184_CR19) 2003; 238 J Guo (184_CR4) 2006; 314 T Nakamura (184_CR24) 2003; 77 EA Kashentseva (184_CR29) 2002; 62 E Vigne (184_CR23) 2003; 10 Y Hattori (184_CR15) 2006; 97 JL Dai (184_CR11) 1996; 61 B Fang (184_CR14) 1998; 273 S Rubinchik (184_CR31) 2003; 76 S Rubinchik (184_CR10) 2001; 8 N Belousova (184_CR20) 2002; 76 184_CR2 184_CR1 VW van Beusechem (184_CR27) 2003; 10 P Henning (184_CR28) 2002; 13 |
References_xml | – volume: 141 start-page: 4698 issue: 12 year: 2000 ident: 184_CR7 publication-title: Endocrinology doi: 10.1210/en.141.12.4698 contributor: fullname: J Zhang – volume: 77 start-page: 2512 issue: 4 year: 2003 ident: 184_CR24 publication-title: J Virol doi: 10.1128/JVI.77.4.2512-2521.2003 contributor: fullname: T Nakamura – volume: 76 start-page: 167 year: 2003 ident: 184_CR31 publication-title: Methods in Molecular Medicine contributor: fullname: S Rubinchik – volume: 7 start-page: 75 issue: 1 year: 2000 ident: 184_CR16 publication-title: Gene Ther doi: 10.1038/sj.gt.3301048 contributor: fullname: S Kagawa – volume: 8 start-page: 342 issue: 5 year: 2001 ident: 184_CR22 publication-title: Cancer Gene Ther doi: 10.1038/sj.cgt.7700313 contributor: fullname: DA Heideman – volume: 5 start-page: 223 issue: 3 year: 2002 ident: 184_CR17 publication-title: Mol Ther doi: 10.1006/mthe.2002.0551 contributor: fullname: L Zhang – volume: 22 start-page: 3285 issue: 6A year: 2002 ident: 184_CR13 publication-title: Anticancer Res contributor: fullname: A Block – volume: 2 start-page: 511 issue: 5 year: 2003 ident: 184_CR18 publication-title: Cancer Biol Ther doi: 10.4161/cbt.2.5.440 contributor: fullname: AL Volk – ident: 184_CR2 – volume: 10 start-page: 153 issue: 2 year: 2003 ident: 184_CR23 publication-title: Gene Ther doi: 10.1038/sj.gt.3301845 contributor: fullname: E Vigne – volume: 108 start-page: 136 issue: 1 year: 2004 ident: 184_CR26 publication-title: Int J Cancer doi: 10.1002/ijc.11563 contributor: fullname: DM Nettelbeck – volume: 76 start-page: 8621 issue: 17 year: 2002 ident: 184_CR20 publication-title: J Virol doi: 10.1128/JVI.76.17.8621-8631.2002 contributor: fullname: N Belousova – volume: 62 start-page: 609 issue: 2 year: 2002 ident: 184_CR29 publication-title: Cancer Res contributor: fullname: EA Kashentseva – volume: 89 start-page: 5547 issue: 12 year: 1992 ident: 184_CR6 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.89.12.5547 contributor: fullname: M Gossen – volume: 11 start-page: 1399 issue: 18 year: 2004 ident: 184_CR5 publication-title: Gene Therapy doi: 10.1038/sj.gt.3302307 contributor: fullname: J Woraratanadharm – volume: 61 start-page: 531 issue: 9 year: 1996 ident: 184_CR11 publication-title: Steroids doi: 10.1016/S0039-128X(96)00086-4 contributor: fullname: JL Dai – volume: 10 start-page: 1982 issue: 23 year: 2003 ident: 184_CR27 publication-title: Gene Ther doi: 10.1038/sj.gt.3302103 contributor: fullname: VW van Beusechem – ident: 184_CR1 – volume: 4 start-page: 416 issue: 5 year: 2001 ident: 184_CR9 publication-title: Mol Ther doi: 10.1006/mthe.2001.0478 contributor: fullname: S Rubinchik – volume: 7 start-page: 875 issue: 10 year: 2000 ident: 184_CR12 publication-title: Gene Ther doi: 10.1038/sj.gt.3301172 contributor: fullname: S Rubinchik – volume: 238 start-page: 815 issue: 6 year: 2003 ident: 184_CR19 publication-title: Ann Surg doi: 10.1097/01.sla.0000098622.47909.c0 contributor: fullname: CJ Buskens – volume: 98 start-page: 298 issue: 5 year: 2006 ident: 184_CR3 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djj111 contributor: fullname: K Garber – volume: 8 start-page: 969 issue: 13 year: 2001 ident: 184_CR21 publication-title: Gene Ther doi: 10.1038/sj.gt.3301473 contributor: fullname: JG Wesseling – volume: 273 start-page: 4972 issue: 9 year: 1998 ident: 184_CR14 publication-title: J Biol Chem doi: 10.1074/jbc.273.9.4972 contributor: fullname: B Fang – volume: 62 start-page: 559 issue: 3 year: 2003 ident: 184_CR25 publication-title: Urology doi: 10.1016/S0090-4295(03)00378-9 contributor: fullname: W Jongmans – volume: 346 start-page: 529 year: 2002 ident: 184_CR30 publication-title: Methods Enzymol doi: 10.1016/S0076-6879(02)46075-2 contributor: fullname: S Rubinchik – volume: 314 start-page: 1232 issue: 5803 year: 2006 ident: 184_CR4 publication-title: Science doi: 10.1126/science.314.5803.1232 contributor: fullname: J Guo – volume: 8 start-page: 247 issue: 3 year: 2001 ident: 184_CR10 publication-title: Gene Ther doi: 10.1038/sj.gt.3301364 contributor: fullname: S Rubinchik – volume: 13 start-page: 1427 issue: 12 year: 2002 ident: 184_CR28 publication-title: Hum Gene Ther doi: 10.1089/10430340260185067 contributor: fullname: P Henning – volume: 1 start-page: 4 issue: 1 year: 1999 ident: 184_CR8 publication-title: J Gene Med doi: 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y contributor: fullname: S Freundlieb – volume: 97 start-page: 787 issue: 8 year: 2006 ident: 184_CR15 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2006.00243.x contributor: fullname: Y Hattori |
SSID | ssj0017806 |
Score | 1.8112146 |
Snippet | Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men. Thus, there is... Abstract Background Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American... BACKGROUND: Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American men.... Abstract Background Despite several effective treatment options available for prostate cancer, it remains the second leading cause of cancer death in American... |
SourceID | doaj pubmedcentral biomedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 9 |
SubjectTerms | Androgen-Binding Protein - genetics Cell Line, Tumor Feedback Gene Expression Regulation, Neoplastic - genetics Gene Silencing Gene Targeting - methods Genetic Therapy - methods Humans Male Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Nucleic Acid Amplification Techniques Promoter Regions, Genetic Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - therapy Protein Engineering Transcription Factors - genetics |
SummonAdditionalLinks | – databaseName: BioMedCentral dbid: RBZ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagXOCAeLM8fUCcsEi8fsRHiqgqJHqiUsXFGsdjsdIqqTZZxA_ghzNOsm0TceOY2B5ZnrHnG3v8mbF3Llha80IUto5WqORABKkqAQ5c0GhCGLayv52Z03P19UJfXJMkLU7wy8p8LJWVgmBtIaxwt9kdmRnOc1h-_OPquMBWxXiNaKp6INNcNl_cat_OnNHA2f8voLnMl7zhgE4esPsTcuSfRlU_ZLewecTu3eATfMz-nLW_cMtHdma-77Dj-cEY6DaNyO4q5k_SDe4-8D47qcOSQXK7zXD9aNdxaCKHnGiepv08vm3bS963nOJ3sgSeKY7FNmcbZXnDlSSOv6eM2uYJOz_58v3zqZieWRBBr11PWsp5VUGmYEAbVCBtrUGjjCppJ2sKcYIGApIUTAJW67qKtMCXLibUDoJaP2VHTdvgc8ajBAmYjJRVIpymACFpGY3FQobaxBVzs_H3lyOlhs8k1_MSmm8-685n3Xnr3Yq9P-jqqtkQwVRmWfE4a3Ime_hBVuWn-eiLsrYBSqxQOYpQS5fASk39ByCErEnI24MdeJpw-RQFGmz3nZeEaiwFkSv2bLSK695QoEIDZlfMzuxl1pN5SbP5OVB6E84qtLQv_mN8XrK7475zfqzmFTvqd3t8TYCpD2-GyfIX-kMZSQ priority: 500 providerName: BioMedCentral – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT-WAoLzC0wfECauJN7bjI1StKiR6olJv1jgei5VWSbXJVvwAfjjjPMpmhcSFY-zEcjxj-xt75hvGPlhvaM3zQZg6GFFGC8LLshJgwXqF2vvhKPvblb68Lr_eqJu9VF_JJ2ykBx4H7jQvauOhwApLS6ZEYSMYqYIEAIIyagzdK9RsTE33B6bKx7giIwVB4nxm16z06X2ZMMIehLlvFrvTQOL_N-R56EC5tyNdPGaPJijJP4-_8IQ9wOaEPdwjGHzKfl21d7jhI10z33XY8ZRBBrp1I9L-FdIjCQu3n3ifdq15DaF2u_UQj7TtODSBQ_I8j9MBH9-07S3vW04GPakGT5zHYpPcj1J7Q4wSx5-Ti23zjF1fnH8_uxRT3gXh1cr2JLbkaOVl9BqUxhKkqRUolKGMysqabB6vgJAlWZeA1aquAq34hQ0RlQVfrp6zo6Zt8CXjJCcJGLWUVSTgVgJCVDJog7n0tQ4Zs4vxd7cjx4ZLrNfLGpqALsnOJdk542zGPs6yuv9sMGkqffjilyTJRdtDAemZm_TM_UvPMvZ-1gNHMzBdq0CD7a5zkmCOIasyYy9GrfjTG7JcaMBMxsxCXxY9WdY06x8DxzcBr1xJ8-p_dP01Ox5PpFMamzfsqN_u8C1Bqd6_G2bNb6HSIXA priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagXOCAeLPl5QPihCHx-hEfEAJEVSG1J1bqzRrHNqwUJSXJonLvD2ecZNlm1QPHJLbleGY839jjz4S8Nk7jnOc806XXTEQDzHFRMDBgnAzKuWEp--RUHa_EtzN5tqMUmgawuza0S_dJrdrq3cWvPx_R4D8MBl-o97nQnCHwzZhm5ia5xcVSJGU_EbsNBV1k40GjqeiWbnO_-t6592rmrgZW_-ug6H5G5RUXdXSP3J2wJf00KsN9ciPUD8idK4yDD8nlafM7VHTkb6abLnQ0XSkD3bpmyaH59IjSC-1b2ic3tp1UsN1uPRxQajsKtaeQUtHjtOJHq6Y5p31DMcJHXaGJBJlVKR8ptTccWqLhYsq5rR-R1dHX71-O2XQRA3NyaXqUY8q8cjw6BVIFAVyXEmTgXkRpeIlBkJOAUBPDTQjFsiw8uoDc-BikASeWj8lB3dThKaGeA4cQFedFRCQnIECU3CsdMu5K5RfEzMbfno-kGzbRYM-_oEXaJDubZGe1NQvyZiurf9WGGKdQ-wU_J0nO2h5eNO0PO1mszfJSO8hDEYTBGDY3ETSX2H8AxNASG3m11QOLJpn2WaAOzaazHHGPxjBzQZ6MWrHrDYYyOGB6QfRMX2Y9mX-p1z8H0m9EYpnk-vB___EZuT0uQ6e7a56Tg77dhBeIn3r3crCMv6ChHc4 priority: 102 providerName: Scholars Portal |
Title | Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression |
URI | https://www.ncbi.nlm.nih.gov/pubmed/17295927 https://search.proquest.com/docview/20247148 http://dx.doi.org/10.1186/1472-6750-7-9 https://pubmed.ncbi.nlm.nih.gov/PMC1810527 https://doaj.org/article/01c7ba1e8e4944819fa725d2aaa50759 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbanuCAeLMUig-IE-4mjh_xkVZUFdJWCFGp4hKNYwdWSpPVJov4Af3hjJ0EmooTl0iJY8vyjD3fjMefCXlrrMY1zzqmS6eZqAwwy0XOwICx0itrYyh7daHOL8WnK3m1R-R0FiYm7Zd2fdzU18fN-kfMrdxcl8spT2z5eXWKVimR6LPvk32dZZOLPm4d6DxRE5lmrpap0JwhKk6YZpEiFNGkNOESmdkB93pmlyJ9_78w593UyVu26OwheTCCSPph6Owjsuebx-T-LWrBJ-Tmov3pazoQNdNd5zsa7o6Bbt2wYLlceEUx-e172gd7Na0e2G63jieRth2FxlEIOefVGNqjddtuaN9SdOVRKWhgO2Z1SDwK7cXTSdT_GpNrm6fk8uzj19NzNt64wKzMTI8CCylWlldWgVReANelBOm5ExUOWonejpWAmBL9SvB5VuYO1_rUuMpLA1Zkz8hB0zb-BaGOAwdfKc7zCiGbAA-V5E5pn3BbKrcgZjb-xWZg1ygC3_W8BKdeEcRYBDEWujAL8m6S1Z9q0ZnJ1d0fT4IkZ23HD-32ezFqVJGkpbaQ-twLg85qairQXGL_ARAsS2zkzaQHBc69sKECjW93XcER4Gj0Jxfk-aAVf3szatmC6Jm-zHoyL0Flj-zeo3K__O-ah-TeEIAOt9a8Igf9dudfI3Lq7VGMOOBzJXJ8fjn5dhTnzm9kLCMv |
link.rule.ids | 108,230,315,733,786,790,870,891,2115,2236,24346,24965,27955,27956,53825,53827,76167,76168 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwGLXGOMAO_GaUX_MBccJt48ZxfISJqcBacdjQbtbn2IGKLKmaFCHO_OF8dhJYKi5wTJxYjvyc73328zMhL5SR-M8zlsnMShbnCpjhccpAgTLCJcaEqezFMpmfx-8vxMUeEf1emCDaz8xqXBaX43L1JWgr15fZpNeJTT4ujjEqTQXm7NfIdRyvXPRJerd4INNp0ttppskkiiVnyIunTLJgEop8Uih_jMxgi3sxiEzBwP9vrHNXPHklGp3cJp_672hFKF_H28aMsx87Fo___KF3yK2On9LXbfFdsufKe-TgimvhffJzWX1zBW09oOm2djX1x9JAvSqZD4rWXyIC3OYVbXwo7H9MWG-9CpucNjWF0lLwcva8mzWkRVWtaVPRVWkRb9QbKbPCa5p8fWHjE3XfO91u-YCcn7w9O56z7jAHZsRMNYgFr94yPDcJiMTFwGUmQDhu4xx7I8NEyghAuor9CS6dZanFMBIpmzuhwMSzh2S_rEr3iFDLgYPLE87THNlgDA5ywW0i3ZSbLLEjogYdq9etcYf2VtrDEhzV2uNDe3xoqdWIvOxB8Pu1kCelye6DbzxEBnWHG9Xms-76UE-jTBqIXOpihXlwpHKQXGD7AZCHC6zkqAeYxmHt12qgdNW21hy5k8RUdUQOW7j9aU0H3xGRAyAOWjIsQXgF4_AOTo__-80jcmN-tjjVp--WH56Qm-08tz8c5ynZbzZb9wwJWmOeh-H4CxV4Qj8 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLVgkBAshudAeY0XiBVuGzeO4yUMVMNjqlkw0oiNdR07ENFJqiYdIdZ8ONdOAk3FapZ5WY58nHuuc3wuIS-VkfjNM5bJzEoW5wqY4XHKQIEywiXGhKXsk0VyfBZ_PBfnW6W-gmg_M8W4XF6My-J70FauLrJJrxObnJ4cYVSaCszZVzafXCc3cM5y2Sfq3Q8EmU6T3lIzTSZRLDlDbjxlkgWjUOSUQvlSMoNt7stBdAom_v9jnrsCyq2INL9Dvvbv0gpRfow3jRlnv3ZsHq_0snfJfsdT6Zv2lnvkmivvk9tb7oUPyO9FdemWtPWCppva1dSXp4G6KJkPjtYfIhLc-jVtfEjsP1DYbl2EzU7rmkJpKXhZe96tHtJlVa1oU9GitIg76g2V2dJrm3x7YQMUdT87_W75kJzN3385OmZdUQdmxEw1iAmv4jI8NwmIxMXAZSZAOG7jHEckw4TKCEDaiqkruHSWpRbDSaRs7oQCE88OyF5Zle4xoZYDB5cnnKc5ssIYHOSC20S6KTdZYkdEDQZXr1oDD-0ttYdXcHZrjxHtMaKlViPyqgfC38dCvpQmuze-9TAZtB1OVOtvuhtHPY0yaSByqYsV5sORykFygf0HQD4usJHDHmQap7f_ZwOlqza15sihJKasI_Kohdy_3nQQHhE5AOOgJ8MrCLFgIN5B6smVnzwkN0_fzfXnD4tPT8mtdrnb18h5Rvaa9cY9R57WmBdhRv4B3hxEvw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+system+uses+probasin-based+promoter%2C+transcriptional+silencers+and+amplification+loop+to+induce+high-level+prostate+expression&rft.jtitle=BMC+biotechnology&rft.au=Woraratanadharm%2C+Jan&rft.au=Rubinchik%2C+Semyon&rft.au=Yu%2C+Hong&rft.au=Dong%2C+John+Y&rft.date=2007-02-12&rft.issn=1472-6750&rft.eissn=1472-6750&rft.volume=7&rft.issue=1&rft_id=info:doi/10.1186%2F1472-6750-7-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_1472_6750_7_9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6750&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6750&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6750&client=summon |